Measles Immunity: How You Get It and How Long It Lasts

Measles immunity comes from two routes: surviving a natural infection or getting vaccinated. Both produce long-lasting protection, but they are not identical. Natural infection triggers a stronger antibody response that persists for life, while vaccination generates somewhat lower antibody levels that can gradually decline over decades, though most vaccinated people remain protected well into adulthood. The story gets more interesting when you look at what each route does to the rest of your immune system, how long maternal antibodies shield newborns, and why even small gaps in vaccine coverage can spark outbreaks.

How Natural Infection Builds Immunity

When wild measles virus enters your body, it triggers an aggressive immune battle. The virus initially depletes your lymphocytes during the acute phase, but this kicks off a massive adaptive immune response: your body churns out measles-specific antibodies and T cells, which eventually clear the active infection and produce the characteristic rash. After the virus is gone, viral RNA lingers in lymphoid tissue, and your immune system continues refining its response through a process that matures the quality and strength of your antibodies over time. The result is life-long immunity.¹

That life-long immunity shows up in the numbers. An Italian study comparing people who had recovered from wild measles to those who had been vaccinated found that the naturally infected group had antibody levels roughly three and a half times higher than the vaccinated group.² This gap matters because higher antibody levels provide a wider margin of safety if you encounter the virus again. But the natural route comes with a steep price, which we’ll get to shortly.

How Vaccination Builds Immunity

The measles vaccine uses a live but weakened (attenuated) version of the virus. It mimics a natural infection closely enough to train your immune system, producing both antibodies and T cell responses that resemble what wild infection generates, just at a lower magnitude.³ The earliest licensed live vaccine, tested in the early 1960s, produced an effective antibody response in more than 95% of susceptible children, though about a third developed temporary fever and rash.⁴ Modern MMR vaccines cause far fewer side effects while maintaining that high conversion rate.

One piece of the puzzle researchers only recently began to understand is that the live attenuated virus doesn’t just stay at the injection site. A study found that vaccine virus RNA was frequently detectable in the respiratory tracts of healthy children and macaques in the weeks after subcutaneous MMR vaccination. Live replicating virus was even isolated from the lungs of two macaques, though there was no evidence it spread to unvaccinated individuals. This suggests the vaccine may build mucosal immunity in the airways, which is exactly where wild measles first attacks.⁵

How Long Vaccine Protection Lasts

The standard two-dose MMR schedule builds durable immunity for most people, but “durable” and “permanent” are not the same thing. In one long-term follow-up, antibodies persisted in all vaccinated children available for testing a full decade after their second dose, with no one testing outright seronegative. However, by the final blood draw, about 5% had antibody levels low enough to be considered potentially susceptible.⁶ A separate study following over 300 participants after their second MMR dose found that about 96% remained seropositive for measles throughout the follow-up period.⁷

So most people keep protective antibody levels for many years after vaccination, but a small fraction gradually slip below the threshold. Among young healthcare workers who were initially seronegative and received booster doses, about 82% had seroconverted and still showed measles antibodies two years later, and roughly half of them had medium or high neutralizing titers.⁸ The takeaway: vaccination works very well for most people, but immunity isn’t a binary switch. It exists on a spectrum, and a small percentage of vaccinated individuals end up on the low end over time.

The Role of Cellular Immunity

Antibody levels get the most attention because they’re the easiest thing to measure in a blood test, but they don’t tell the whole story. Your immune system also maintains measles-specific T cells, which can recognize and attack virus-infected cells even if your antibody levels have dipped. A study of young adults who had received two MMR doses found persistent measles-specific T cell responses, and those cellular immunity measures did not correlate with antibody concentrations.⁹ In other words, someone whose antibodies have dropped may still have robust T cell protection that would kick in upon exposure.

Research in Brazilian children eight years after their first MMR dose confirmed this pattern: while antibody concentrations declined over time, their immune cells still mounted a measles-specific response when stimulated in the lab, and neutralizing antibody activity against circulating virus strains persisted.¹⁰ This is why people with borderline antibody levels are not necessarily unprotected. The immune system has backup layers.

The Hidden Cost of Natural Immunity

Here is where advocating for “natural immunity” over vaccination runs into a serious problem. Wild measles doesn’t just teach your immune system about measles; it also erases some of what your body already knew about other diseases. A landmark study found that measles infection wiped out between 11% and 73% of a person’s existing antibody repertoire, depending on the individual. This phenomenon, known as immune amnesia, means that after recovering from measles, you become more vulnerable to infections you were previously protected against, from flu to bacterial pathogens you’d encountered years earlier.¹¹

Vaccination does not cause this immune amnesia. The attenuated vaccine virus trains your immune system against measles without the collateral damage to existing immune memory. This is one of the most underappreciated arguments for vaccination: it’s not just about measles itself, it’s about protecting the immunity you’ve already built against everything else.

Why Re-Exposure Helps Maintain Immunity

In the pre-vaccine era, people who had survived measles maintained high antibody levels partly because the virus was constantly circulating. Each time they encountered it again in the community, even without getting sick, their immune system got a silent booster. A study of late convalescent measles patients found that those who were not re-exposed to wild virus saw their antibody levels decline by about 12% over six years, while those who encountered wild virus again maintained stable levels without showing any signs of a new infection.¹²

This creates a paradox for the vaccine era. As vaccination drives measles toward elimination, there are fewer wild viruses circulating to provide those natural boosts. Vaccinated individuals, who start with lower antibody levels than naturally infected people, are particularly affected by this lack of periodic reinforcement. It’s one reason researchers are paying attention to whether antibody levels in highly vaccinated populations could gradually drift downward over generations.

Babies and the Maternal Antibody Window

Newborns inherit measles antibodies from their mothers through the placenta. How long this borrowed protection lasts depends heavily on how much antibody the mother had. A multi-country study found that while 94% of newborns had protective antibody levels at birth, those levels varied widely and dropped fast. By about two and a half to six months of age, depending on the country, the average infant’s antibody level had fallen below the protective threshold. By six months, fewer than half of infants in most countries studied still had adequate protection.¹³

This matters because the standard first MMR dose is given at 12 to 15 months of age in most countries. That leaves a gap of several months where many infants have no protection from either maternal antibodies or their own vaccination. In Bangladesh, researchers found that by five months of age, two-thirds of infants had essentially no protective antibody left.¹⁴ During outbreaks, this vulnerability window becomes especially dangerous.

Why not just vaccinate earlier? Because remaining maternal antibodies can interfere with the vaccine’s ability to generate a strong response. Children vaccinated before 12 months tend to develop lower antibody levels, and this reduced response can persist even after the second dose.¹⁵ Still, in outbreak settings, early vaccination at six months can be worthwhile. Studies of infants vaccinated at six months found that nearly all had protective antibody levels by 27 months of age after receiving a follow-up dose at 15 months.¹⁶ The trade-off is real, but in high-risk situations, early vaccination can bridge the gap.

When Vaccine Immunity Fails

Vaccine failure falls into two categories. Primary vaccine failure means the vaccine never generated an adequate immune response in the first place. Secondary vaccine failure means the person initially responded well but their immunity waned over time until it was no longer protective. An analysis of breakthrough measles cases in an elimination setting classified about 54% as primary vaccine failures and 31% as secondary vaccine failures, with the remainder unclassifiable.¹⁷

Primary failure is the more common problem and is partly why the two-dose schedule exists. A single dose catches most people, and the second dose mops up the majority of those who didn’t respond the first time. Between the two doses, vaccine effectiveness against infection approaches 99.7%.¹⁸ Secondary failure, while less common, is the type that concerns public health officials as time passes in elimination settings where there’s no wild virus circulating to provide natural boosts.

The 95% Threshold

Measles is extraordinarily contagious, which sets a high bar for herd immunity. The basic reproduction number describes how many people one infected person would infect in a fully susceptible population. For measles, that number has historically been cited as somewhere around 12 to 18, but some analyses in specific settings have estimated it considerably higher. One study of a German school outbreak calculated the value at about 31, suggesting that vaccination coverage above 95% may be needed to achieve herd immunity.¹⁸ Even small pockets of unvaccinated or under-vaccinated individuals can sustain outbreaks, because the virus is so efficient at finding susceptible people.

This is why countries aim for 95% coverage with two doses. The target sounds abstract until you realize that every percentage point below it represents a meaningful increase in outbreak risk. Communities with 90% coverage might seem well-protected on paper, but in a confined setting like a school or daycare, those remaining susceptible individuals can sustain a chain of transmission.

People Who Lose Their Immunity

Certain medical situations can erase measles immunity even if you were fully vaccinated or previously infected. Bone marrow transplant recipients are the clearest example. A study tracking allogeneic bone marrow transplant patients found that the probability of still being immune to measles dropped to about 47% at three years after transplant and just 20% by seven years, regardless of whether the donor had been immune.¹⁹ The transplant essentially replaces the patient’s immune system, and the new immune cells don’t carry the old memory. This is why revaccination guidelines exist for transplant recipients, typically starting about a year after transplant once the new immune system has stabilized.

Other immunocompromised populations face similar challenges. People on certain immunosuppressive drugs, those with advanced HIV, and patients undergoing chemotherapy can all see their measles immunity diminished. These groups rely heavily on the herd immunity provided by the vaccinated people around them.

Checking Your Immunity

If you’re unsure about your measles protection, particularly if you were born during the transition period between the one-dose and two-dose vaccine schedules, or if you have medical records that are incomplete, a blood test can measure your measles IgG antibodies. A positive result generally means you have some level of protection. However, commercial tests don’t all agree, especially for people with low-positive antibody levels. A comparison of commercial measles IgG assays found good agreement for clearly negative and clearly positive samples, but discrepant results for samples in the low-positive range of the most sensitive tests.²⁰

This means a borderline result can be hard to interpret. One lab might call you positive while another calls you equivocal. And as noted earlier, antibody levels alone don’t capture your T cell immunity, which might still protect you even if antibodies are low. The practical advice is straightforward: if your results are equivocal or negative, getting an MMR dose is safe and effective even for adults, and there’s no harm in receiving the vaccine if you already have some immunity.

The Third-Dose Question

With measles resurging in some regions, researchers have explored whether a third MMR dose could shore up waning immunity in adults. Some studies suggest that a third dose can boost both antibody and T cell responses in people whose levels have declined. However, the evidence so far comes mostly from small, context-specific studies and does not yet demonstrate lasting clinical protection or a measurable impact on transmission at the population level.²¹ A few countries have recommended a third dose during outbreaks for certain high-risk groups, like healthcare workers, but this has not become a routine recommendation anywhere.

Why Some People Respond Differently to the Vaccine

Not everyone builds the same level of immunity after vaccination, and genetics are part of the reason. Variations in certain immune-system genes, particularly the HLA genes that help your immune cells recognize foreign invaders and genes that regulate inflammatory signaling molecules, influence how strong your antibody and T cell responses are after MMR vaccination.²² Variations in the CD46 gene, which encodes a protein that the measles virus uses to enter cells, also play a role. This genetic variability is one reason why a small percentage of people remain poor responders even after two doses.

Interestingly, body mass index does not appear to be a significant factor. A study that adjusted for sex, age at vaccination, and age at enrollment found no association between BMI and loss of measles protection after MMR vaccination.²³ This is reassuring given the well-documented effects of obesity on immune responses to some other vaccines, including influenza and hepatitis B. For measles, at least, your weight doesn’t seem to predict how well or how long your vaccine protection holds up.